| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JMP Securities analyst Silvan Tuerkcan maintains Terns Pharma (NASDAQ:TERN) with a Market Outperform and lowers the price ta...
Terns Pharmaceuticals announces 12-week Phase 2 results for oral obesity drug TERN-601, showing up to 4.6% weight loss but repo...
Barclays analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Overweight and lowers the price target from $15 to...
Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse eventsAsymptomatic,...
Truist Securities analyst Srikripa Devarakonda initiates coverage on Terns Pharma (NASDAQ:TERN) with a Buy rating and announ...